Category: Press Release

2019.09.10

I-Mab Biopharma and Junshi Biosciences Announce Collaboration to Evaluate TJD5 in Combination with Toripalimab for the Treatment of Patients with Cancers in China

2019.08.01

I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors

2019.07.13

I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China

2019.07.11

MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

2019.06.26

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

2019.04.29

I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma

2019.04.17

I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

2019.04.11

I-Mab Biopharma Signs Agreement for Clinical Research of TJD5 in Combination Therapy

2019.04.08

I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center

2019.03.20

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma